OncoMatch/Clinical Trials/NCT06958328
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Is NCT06958328 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for locally advanced unresectable pancreatic ductal adenocarcinoma.
Treatment: Capecitabine · Fluorouracil · Gemcitabine · Irinotecan Hydrochloride · Irinotecan Sucrosofate · Leucovorin Calcium · Nab-paclitaxel · Oxaliplatin — This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy (FOLFIRINOX, NALIRIFOX, gemcitabine/nab-paclitaxel) — first-line
the patient must have received 4-6 months of active chemotherapy with FOLFIRINOX or NALIRIFOX or gemcitabine/nab-paclitaxel
Cannot have received: radiation therapy
Exception: Prior non-overlapping radiation (e.g., breast, head and neck, extremity) is permitted
Has the patient had prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Lab requirements
Liver function
ALT and AST ≤ 3 x upper limit of normal (ULN); baseline CA19-9 and bilirubin requirements as specified
Cardiac function
No cardiac condition that was the primary reason for hospitalization in the last 6 months; NYHA Functional Classification II or better
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); baseline CA19-9 and bilirubin requirements as specified; No cardiac condition that was the primary reason for hospitalization in the last 6 months; New York Heart Association Functional Classification II or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
- UC San Diego Moores Cancer Center · La Jolla, California
- Memorial Medical Center · Modesto, California
- Palo Alto Medical Foundation-Camino Division · Mountain View, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify